Zevra Therapeutics
ZVRA

$8.06

0.5%

Market Cap: $424M

About: Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Employees: 69

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

228% more call options, than puts

Call options by funds: $985K | Put options by funds: $300K

200% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 14

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

11% more capital invested

Capital invested by funds: $81.2M [Q1] → $90.4M (+$9.21M) [Q2]

9.61% more ownership

Funds ownership: 34.51% [Q1] → 44.12% (+9.61%) [Q2]

4% more funds holding

Funds holding: 89 [Q1] → 93 (+4) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

86%

upside

Avg. target

$18.75

133%

upside

High target

$22

173%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Oren Livnat 44% 1-year accuracy 17 / 39 met price target	148%upside $20	Buy Maintained	20 Sept 2024
Canaccord Genuity Sumant Kulkarni 52% 1-year accuracy 12 / 23 met price target	173%upside $22	Buy Maintained	18 Sept 2024
HC Wainwright & Co. Oren Livnat 44% 1-year accuracy 17 / 39 met price target	123%upside $18	Buy Maintained	5 Aug 2024
HC Wainwright & Co. Oren Livnat 44% 1-year accuracy 17 / 39 met price target	86%upside $15	Buy Reiterated	9 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ZVRA published over the past 30 days

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

US FDA approves Zevra's genetic disorder treatment

The U.S. Food and Drug Administration approved Zevra Therapeutics' drug for a rare and fatal genetic disorder, the first treatment to get a nod for the condition, the health regulator said on Friday.

US FDA approves Zevra's genetic disorder treatment

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease progression

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Zevra Therapeutics to Participate at Upcoming Investor Conferences

CELEBRATION, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Office of Zevra, will present at upcoming investor conferences during the month of September 2024. Additionally, management will be available for one-on-one meetings with registered attendees at each conference.

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Nicole Oschner - Vice President of Investor Relations and Corporate Communications Neil McFarlane - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Josh Schafer - Chief Commercial Officer and Executive Vice President of Business Development Conference Call Participants Louise Chen - Cantor Fitzgerald Tim Lugo - William Blair Oren Livnat - H.C. Wainwright Operator Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call.

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.15 per share a year ago.

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of $6.50 per share, for total gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

CELEBRATION, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (“Zevra”), today announced the commencement of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Zevra. Zevra also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

CELEBRATION, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at Canaccord Genuity's 44th Annual Growth Conference in Boston, MA, on Wednesday, August 14, 2024, at 10:30 a.m. ET. Members of the executive team will be available for one-on-one investor meetings with registered attendees throughout the conference.

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

Zacks Investment Research

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

See News Rankings